Portola Pharmaceuticals Inc (PTLA) 23.95 $PTLA
Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 12, 3:08PM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today provided a corporate update and reported its financial results for the quarter ended March 31, 2014.
Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO(R)
GlobeNewswire - Mon May 12, 7:11AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that enrollment has begun in a Phase 3 study to evaluate the safety and efficacy of andexanet alfa, the Company's investigational recombinant Factor Xa inhibitor reversal agent, with Bayer HealthCare and Janssen Pharmaceuticals Inc.'s Factor Xa inhibitor XARELTO (rivaroxaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class agent to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery.
Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Mon May 12, 6:55AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that William Lis, chief executive officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on Thursday, May 15, 2014, at 10:00 a.m. Pacific Time.
Commit To Purchase Portola Pharmaceuticals At $20, Earn 15.4% Annualized Using Options
at The Street - Fri May 09, 10:41AM CDT
Investors considering a purchase of Portola Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $23.20/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Portola Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
GlobeNewswire - Mon May 05, 8:42AM CDT
Portola Pharmaceuticals, Inc. (Nasdaq TLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2014 and provide a general business overview on Monday, May 12, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Thrombocytopenia Therapeutic Pipeline Review 2014 - Analysis of 20 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2wbjx/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - BioLineRx, Ltd. - Eisai Co., Ltd. - Octapharma AG - Ono Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Portola Pharmaceuticals, Inc. - Uni-Bio Science Group Ltd. - Cellerant Therapeutics, Inc. - Bolder Biotechnology, Inc. - Genelux Corporation - ViroMed Co., Ltd. - aTyr Pharma, Inc. - Neumedicines Inc. - Tarix Pharmaceuticals LTD. - STATegics, Inc. - Prophylix Pharma AS - InvivoGen Therapeutics - Myelo Therapeutics GmbH Drug Profiles - avatrombopag - lusutrombopag - immune globulin (human) - VM-501 - UNI-rhIL-11 - NL-201 - eltrombopag olamine - lusutrombopag - avatrombopag - ONO-7746 - GLONC-4 - CBLB-612 - BBT-030 - BBT-045 - NMIL-121 - PEG-VM501 - PanCyte - Tmax - Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - BL-8040 - STST-4 - CLT-009 - PRT-060318 - Myelo-001 - Tromplate For more information visit http://www.researchandmarkets.com/research/z2...ocytopenia
Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal.Betrixaban, the Company's wholly-owned, oral, once-daily Factor Xa anticoagulant, is being evaluated in the only ongoing global, pivotal study of in-hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in patients who have been hospitalized for medical conditions, such as heart failure, stroke, infection and pulmonary disease.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks That Escaped Biotech's March Madness
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but there were a few biotech stocks that soared. Among them were Agios Pharmaceuticals , Chimerix, Inc. , and Portola Pharmaceuticals . All three shrugged off the broad biotech sell-off that...
An Interview With Portola Pharmaceuticals CEO Bill Lis
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 28, 11:22AM CDT
Portola Pharmaceuticals is relatively new to biotech investors and was one of many biotechs to IPO last year. In an effort to better understand the company's pipeline and upcoming catalysts, analyst Max Macaluso recently spoke with the company's...
Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies.
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliquis(apixaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies.
Portola Pharmaceuticals elects John H. Johnson to board
M2 - Wed Mar 19, 6:42AM CDT
Biopharmaceutical company Portola Pharmaceuticals (NasdaqGS TLA) revealed on Tuesday the addition of John H. Johnson to its board of directors, effective 26 March 2014.
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation.
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 12, 3:08PM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today provided a corporate update and reported its financial results for the quarter ended March 31, 2014. Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO(R)
GlobeNewswire - Mon May 12, 7:11AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that enrollment has begun in a Phase 3 study to evaluate the safety and efficacy of andexanet alfa, the Company's investigational recombinant Factor Xa inhibitor reversal agent, with Bayer HealthCare and Janssen Pharmaceuticals Inc.'s Factor Xa inhibitor XARELTO (rivaroxaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class agent to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery. Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Mon May 12, 6:55AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that William Lis, chief executive officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on Thursday, May 15, 2014, at 10:00 a.m. Pacific Time. Commit To Purchase Portola Pharmaceuticals At $20, Earn 15.4% Annualized Using Options
at The Street - Fri May 09, 10:41AM CDT
Investors considering a purchase of Portola Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $23.20/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Portola Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
GlobeNewswire - Mon May 05, 8:42AM CDT
Portola Pharmaceuticals, Inc. (Nasdaq
TLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2014 and provide a general business overview on Monday, May 12, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Thrombocytopenia Therapeutic Pipeline Review 2014 - Analysis of 20 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2wbjx/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - BioLineRx, Ltd. - Eisai Co., Ltd. - Octapharma AG - Ono Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Portola Pharmaceuticals, Inc. - Uni-Bio Science Group Ltd. - Cellerant Therapeutics, Inc. - Bolder Biotechnology, Inc. - Genelux Corporation - ViroMed Co., Ltd. - aTyr Pharma, Inc. - Neumedicines Inc. - Tarix Pharmaceuticals LTD. - STATegics, Inc. - Prophylix Pharma AS - InvivoGen Therapeutics - Myelo Therapeutics GmbH Drug Profiles - avatrombopag - lusutrombopag - immune globulin (human) - VM-501 - UNI-rhIL-11 - NL-201 - eltrombopag olamine - lusutrombopag - avatrombopag - ONO-7746 - GLONC-4 - CBLB-612 - BBT-030 - BBT-045 - NMIL-121 - PEG-VM501 - PanCyte - Tmax - Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - BL-8040 - STST-4 - CLT-009 - PRT-060318 - Myelo-001 - Tromplate For more information visit http://www.researchandmarkets.com/research/z2...ocytopenia
Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal.Betrixaban, the Company's wholly-owned, oral, once-daily Factor Xa anticoagulant, is being evaluated in the only ongoing global, pivotal study of in-hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in patients who have been hospitalized for medical conditions, such as heart failure, stroke, infection and pulmonary disease. Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks That Escaped Biotech's March Madness
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but there were a few biotech stocks that soared. Among them were Agios Pharmaceuticals , Chimerix, Inc. , and Portola Pharmaceuticals . All three shrugged off the broad biotech sell-off that...
An Interview With Portola Pharmaceuticals CEO Bill Lis
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 28, 11:22AM CDT
Portola Pharmaceuticals is relatively new to biotech investors and was one of many biotechs to IPO last year. In an effort to better understand the company's pipeline and upcoming catalysts, analyst Max Macaluso recently spoke with the company's...
Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies. Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliquis(apixaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies. Portola Pharmaceuticals elects John H. Johnson to board
M2 - Wed Mar 19, 6:42AM CDT
Biopharmaceutical company Portola Pharmaceuticals (NasdaqGS
TLA) revealed on Tuesday the addition of John H. Johnson to its board of directors, effective 26 March 2014. Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation. 5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
